Nantahala Capital Management LLC Makes New Investment in ADMA Biologics Inc $ADMA

Nantahala Capital Management LLC purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, HoldingsChannel reports. The institutional investor purchased 2,359,993 shares of the biotechnology company’s stock, valued at approximately $19,753,141.

Several other hedge funds have also made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of ADMA Biologics in the second quarter valued at $321,037,000. Janus Henderson Group PLC lifted its position in ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after buying an additional 3,838,158 shares during the period. Capital Research Global Investors boosted its stake in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Caligan Partners LP purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $38,653,000. Finally, UBS Group AG grew its holdings in ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after buying an additional 2,581,670 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $9.34 on Friday. The stock’s 50-day moving average is $9.07 and its 200-day moving average is $10.54. The company has a market cap of $2.09 billion, a price-to-earnings ratio of 13.34 and a beta of 0.74. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same period in the previous year, the company posted $0.14 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. Equities analysts anticipate that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ADMA shares. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Raymond James Financial started coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Mizuho dropped their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.